<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=11521&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="284550" class="table-">
                
                <td>Nov. 26, 2021, 10:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: Adult cohort: Phase 2 part: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] Manufacturer: DS manufactured by Novavax and DP (fill finish) by SIIPL.Phase 3 part:COVOVAX; Manufacturer: Serum Institute of India Pvt. Ltd.Pediatric cohort: Test vaccine: COVOVAX; DS and DP manufactured by SIIPLControl Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl Intervention2: Placebo: Adult Cohort (Phase 2 part) and Pediatric Cohort: Placebo: 0.9% Normal saline (Sodium chloride) for injection.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: Adult cohort: Phase 2 part: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] Manufacturer: DS manufactured by Novavax and DP (fill finish) by SIIPL.Phase 3 part:COVOVAX; Manufacturer: Serum Institute of India Pvt. Ltd.Pediatric cohort: Test vaccine: COVOVAX; DS and DP manufactured by SIIPLControl Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl Intervention2: Placebo: Adult Cohort (Phase 2 part) and Pediatric Cohort: Placebo: 0.9% Normal saline (Sodium chloride) for injection.&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}, {&quot;arm_notes&quot;: &quot;5mcg+50mcg;2;Days1-22 (COVOVAX )&quot;, &quot;treatment_id&quot;: 1158, &quot;treatment_name&quot;: &quot;Sars-cov-2 rs/matrix-m1 adjuvant&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;5mcg+50mcg;2;Days1-22 (Novavax)&quot;, &quot;treatment_id&quot;: 1158, &quot;treatment_name&quot;: &quot;Sars-cov-2 rs/matrix-m1 adjuvant&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="275631" class="table-">
                
                <td>Nov. 13, 2021, 5:33 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;N/A&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="243833" class="table-">
                
                <td>March 26, 2021, 2:21 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticlevaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] is available as aready to use liquid formulation in a vial containing 5 mcg antigen and 50 mcgMatrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcgMatrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Serum Institute of India Pvt. Ltd. (SIIPL).Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl Intervention2: Placebo: Placebo: 0.9%Normal saline (Sodium chloride) for injection. Each dose of 0.5 ml will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticlevaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] is available as aready to use liquid formulation in a vial containing 5 mcg antigen and 50 mcgMatrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcgMatrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Serum Institute of India Pvt. Ltd. (SIIPL).Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl Intervention2: Placebo: Placebo: 0.9%Normal saline (Sodium chloride) for injection. Each dose of 0.5 ml will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: Adult cohort: Phase 2 part: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] Manufacturer: DS manufactured by Novavax and DP (fill finish) by SIIPL.Phase 3 part:COVOVAX; Manufacturer: Serum Institute of India Pvt. Ltd.Pediatric cohort: Test vaccine: COVOVAX; DS and DP manufactured by SIIPLControl Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl Intervention2: Placebo: Adult Cohort (Phase 2 part) and Pediatric Cohort: Placebo: 0.9% Normal saline (Sodium chloride) for injection.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: Adult cohort: Phase 2 part: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] Manufacturer: DS manufactured by Novavax and DP (fill finish) by SIIPL.Phase 3 part:COVOVAX; Manufacturer: Serum Institute of India Pvt. Ltd.Pediatric cohort: Test vaccine: COVOVAX; DS and DP manufactured by SIIPLControl Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Adult Cohort: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant. DS and DP manufactured by NovavaxControl Intervention2: Placebo: Adult Cohort (Phase 2 part) and Pediatric Cohort: Placebo: 0.9% Normal saline (Sodium chloride) for injection.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "5mcg+50mcg;2;Days1-22 (COVOVAX )", "treatment_id": 1158, "treatment_name": "Sars-cov-2 rs/matrix-m1 adjuvant", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5mcg+50mcg;2;Days1-22 (Novavax)", "treatment_id": 1158, "treatment_name": "Sars-cov-2 rs/matrix-m1 adjuvant", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
Nov. 13, 2021, 5:33 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]
March 26, 2021, 2:21 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticlevaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] is available as aready to use liquid formulation in a vial containing 5 mcg antigen and 50 mcgMatrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcgMatrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Serum Institute of India Pvt. Ltd. (SIIPL).Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl Intervention2: Placebo: Placebo: 0.9%Normal saline (Sodium chloride) for injection. Each dose of 0.5 ml will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant]: COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticlevaccine (SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 adjuvant] is available as aready to use liquid formulation in a vial containing 5 mcg antigen and 50 mcgMatrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcgMatrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Serum Institute of India Pvt. Ltd. (SIIPL).Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant: Novavax-SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(SARS-CoV-2 rS) with Matrix-M1\u00e2?\u00a2 Adjuvant is available as a ready touse liquid formulation in a vial containing 5 mcg antigen and 50 mcg Matrix-M1 adjuvant. Each dose of 0.5 ml (5 mcg antigen and 50 mcg Matrix-M1 adjuvant) will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.Manufacturer: Novavax; USAControl Intervention2: Placebo: Placebo: 0.9%Normal saline (Sodium chloride) for injection. Each dose of 0.5 ml will be given intramuscularly on deltoid on Day 1 and Day 22 as per randomization.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]